Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

OPTIMAL Pain & Regenerative Medicine Now Offering a New FDA-Approved Spinal Cord Stimulator to Treat Leg and Back Pain
  • USA - English


News provided by

OPTIMAL Pain & Regenerative Medicine

Aug 04, 2016, 07:00 ET

Share this article

Share toX

Share this article

Share toX

Senza® HF10 Therapy System
Senza® HF10 Therapy System

Arlington, Texas (PRWEB) August 04, 2016 -- Drs. Berlin, Cottingham and Phillips at OPTIMAL Pain & Regenerative Medicine are now offering a new FDA-approved spinal cord stimulator developed by Nevro known as the Senza® HF10 therapy to treat patients in the Dallas, Ft. Worth and Arlington, Texas area who are suffering from chronic back pain and leg pain. HF10 therapy is the first spinal cord stimulator that is paresthesia-free and is clinically proven to eliminate back and leg pain.

"HF10 therapy has been a revolutionary advancement in spinal cord stimulation and pain control," said Dr. Andrew Cottingham

Post this

According to a study released last year by the National Institute of Health’s National Center for Complementary and Integrative Health, nearly 50 million American adults suffer from daily chronic pain or severe pain. Since 1967, spinal cord stimulation technology has been used to treat chronic back pain and leg pain. In May of 2015, the FDA approved the new HF10 therapy by Nevro. This treatment is the first spinal cord stimulator completely paresthesia-free, which means the stimulation-­induced sensation, such as tingling, burning or pricking seen in many traditional spinal cord stimulators is gone.

"In the past, spinal cord stimulators caused paraesthesias and lost efficacy in as little as six months for some patients,” said Dr. Andrew Cottingham. “Patients also needed a remote control to frequently adjust their settings. HF10 therapy has been a revolutionary advancement in spinal cord stimulation and pain control. Now patients can have drastically improved, long-term relief of chronic back, neck and/or extremity pain without the paraesthesias or need for a remote control."

Patients who have chronic back and leg pain experience abnormal pain signals that are sent through the spinal cord and into the brain. HF10 therapy calms the nerves that carry these signals to provide lasting pain relief. In a simple procedure, thin insolated wires are inserted in the back near the spinal cord and connected to a compact battery-operated pulse generator, which is implanted just under the skin. HF10 therapy sends mild electronic pulses to the spinal cord to calm the nerves returning them to a more normal state.

Pain management physician Dr. Berlin said, "High frequency spinal cord stimulation has dramatically changed our outcomes for treating patients with low back pain with or without leg symptoms. In the past, patients have had limited choices for long-term pain relief for chronic low back pain. Our experience with HF-10 therapy so far has been remarkable. Most of our patients implanted with this new technology have been completely weaned from all their narcotic analgesics and have returned to a normal drug free life. Many of our patients remark that they are pain free for the first time in years."

A study by the Journal of the America Society of Anesthesiologists found that HF10 therapy lead to a substantially positive impact on the management of back and leg pain. 8 out of 10 patients who have used HF10 therapy experience significant, lasting relief from back and leg pain allowing patients to return to their everyday activities.

The HF10 therapy procedure is quick, minimally invasive and may not require a hospital stay. Patients who have gone through failed surgery, or failed pain management treatments to alleviate back pain and leg pain are strong candidates for HF10 therapy. Before fully committing to the treatment, the doctors at OPTIMAL will assess the effectiveness for each individual patient. 9 out of 10 patients who try HF10 therapy stick with the treatment.

To learn if you are a candidate for HF10 therapy, please click here: HF10 Therapy.

About OPTIMAL Pain & Regenerative Medicine

Regenerative medicine physicians Dr. Scott Berlin, Dr. Andrew Cottingham and Dr. Michael Phillips strive to be at the forefront in providing leading edge interventional pain management and regenerative medicine options to patients in Dallas, Ft. Worth and Arlington. All double board certified in anesthesiology and pain medicine, their collective expertise includes a full range of treatment options. No matter what your stage of life, OPTIMAL delivers comprehensive, current and most importantly, compassionate medical care.

Kristin Mapstone, OPTIMAL Pain & Regenerative Medicine, http://optimaldfw.com, +1 214-293-6581, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.